C-ONC

T:ONC - ONCOLYTICS BIOTECH INC. - http://www.oncolyticsbiotech.com

13:46:58 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
ONC - T	0.4	1.61	·	1.62	37.4	1.62	+0.02	1.3	13.4	19	62	1.61 1.62 1.60	4.49 1.20	13:14:36	Apr 25	15 min RT 2¢
TSX - T	0.4	1.61	·	1.62	37.4	1.62	+0.02	1.3	9.8	14	41	1.61 1.62 1.60	4.49 1.20	13:14:36		15 min
Alpha - A						1.62	+0.02	1.3	2.5	4	1	1.62 1.62 1.62		10:32:56		15 min
Chi-X - X						1.61	+0.01	0.6	0.6	1	2	1.61 1.61 1.61		10:19:46		15 min
CXD - D						1.60			0.2	0	9			Apr 23		15 min
TriAct - M						1.60			0.2	0	9			Sep 11-20		15 min

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
NOTE: Delayed ATS trade data is included - click System Status for more information

Hide ATS · Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · Company · Participants · 1yr Bulletins · Sedar · Historical · Options · Shorts · Portfolio

Recent Trades - Last 10 of 62

More trades...

Time ET	Ex	Price	Change	Volume	Buyer	Seller	Markers
13:14:36	T	1.62	0.02	1,000	7 TD Sec	7 TD Sec	K
13:12:44	D	1.61	0.01	20	80 National Bank	80 National Bank	E
13:12:44	T	1.61	0.01	100	1 Anonymous	7 TD Sec	K
13:12:44	T	1.61	0.01	200	1 Anonymous	7 TD Sec	K
13:03:48	T	1.61	0.01	100	14 Virtu ITG	7 TD Sec	K
12:55:36	M	1.61	0.01	8	7 TD Sec	7 TD Sec
12:52:38	D	1.60		28	7 TD Sec	7 TD Sec	E
12:52:38	T	1.60		100	79 CIBC	7 TD Sec	K
12:40:53	T	1.61	0.01	100	1 Anonymous	124 Questrade	K
12:40:53	T	1.61	0.01	200	1 Anonymous	7 TD Sec	K

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Price	Type	Headline
2024-04-05 07:12	C:ONC	1.56	In the News525	Globe says Oncolytics Biotech kept at "outperformer"
2024-03-12 16:33	C:ONC	1.43	SEDAR Annual Report803	SEDAR Annual Report
2024-03-07 19:18	C:ONC	1.41	SEDAR Audited Annual Financial Statements804	SEDAR Audited Annual Financial Statements
2024-03-07 19:18	C:ONC	1.41	SEDAR MD & A815	SEDAR MD & A
2024-03-07 16:22	C:ONC	1.41	News Release200	Oncolytics spends $17.7-million on R&D in 2023
2024-03-05 10:34	C:ONC	1.37	News Release200	Oncolytics files amendment to Goblet phase 1/2 study
2024-03-04 10:48	C:ONC	1.51	News Release200	Oncolytics Biotech to release 2023 results March 7
2024-02-14 11:37	C:ONC	1.41	News Release200	Oncolytics expands Goblet anal cancer study enrolment
2024-01-09 10:31	C:ONC	1.81	News Release200	Oncolytics Biotech appoints Andrews as director
2024-01-04 09:40	C:ONC	1.76	News Release200	Oncolytics Biotech recaps 2023 operations
2023-12-07 10:16	C:ONC	1.91	News Release200	Oncolytics presents AWARE-1 data at cancer symposium
2023-11-09 10:43	C:ONC	1.82	News Release200	Oncolytics presents Goblet results at IMACC in Rome
2023-11-09 10:03	C:ONC	2.15	News Release200	Oncolytics plans to start phase 3 PDAC study mid-2024
2023-11-03 13:38	C:ONC	2.35	News Release200	Oncolytics Biotech presents Aware-1 study data
2023-11-03 11:33	C:ONC	2.43	SEDAR Interim MD & A813	SEDAR Interim MD & A
2023-11-03 11:31	C:ONC	2.43	SEDAR Interim Financial Statements812	SEDAR Interim Financial Statements
2023-11-03 11:23	C:ONC	2.35	News Release200	Oncolytics Biotech's Sept. 30 cash at $40-million
2023-10-23 11:04	C:ONC	2.30	News Release200	Oncolytics talks Goblet pancreatic cancer study data
2023-10-23 10:18	C:ONC	2.14	News Release200	Oncolytics' Goblet study meets efficacy criteria
2023-10-20 08:06	C:ONC	2.22	News Release200	Oncolytics Biotech to release Q3 2023 results Nov. 3

Date ET

Symbol

Price

Type

Headline

2024-04-05 07:12

C:ONC

1.56

In the News

Globe says Oncolytics Biotech kept at "outperformer"

2024-03-12 16:33

C:ONC